Mikołaj Słabicki, PhD
Dr. Mikołaj Słabicki received his Master’s degree from the Technical University of Łódź and earned his Ph.D. under the supervision of Dr. Frank Buchholz at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. He then completed postdoctoral research at NCT/DKFZ in Heidelberg, followed by a fellowship as a Marie Skłodowska-Curie Scholar in Dr. Benjamin Ebert’s lab at the Dana-Farber Cancer Institute, and in Dr. Stefan Fröhling’s lab at the German Cancer Research Center in Heidelberg. Dr. Słabicki later became a Group Leader in the Cancer Program at the Broad Institute of MIT and Harvard. In the summer of 2024, he joined the Massachusetts General Hospital (MGH) Krantz Family Center for Cancer Research as a faculty member. His laboratory focuses on expanding the druggable proteome by using functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques to discover and characterize new molecular glue degraders and novel mechanisms of targeted protein degradation.